Cargando…

Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review

Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy and is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney failure. The complement cascade plays an integral role in aHUS. Mutations in the complement cascade, especially in the alter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahid, Kamran, Qayyum, Shahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613336/ https://www.ncbi.nlm.nih.gov/pubmed/37905269 http://dx.doi.org/10.7759/cureus.46185

Ejemplares similares

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
por: Mauch, Teri J, et al.
Publicado: (2023)

The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)

Atypical Hemolytic Uremic Syndrome Associated With Clostridium Difficile Infection
por: Khurshid, Qasim, et al.
Publicado: (2020)

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
por: Jalbert, Arielle, et al.
Publicado: (2023)

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
por: Tomazos, Ioannis, et al.
Publicado: (2022)

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)

Atypical Hemolytic Uremic Syndrome: A Case Report
por: Mohammed, Sohaib K, et al.
Publicado: (2019)

Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult
por: Alhabhbeh, Ammar, et al.
Publicado: (2021)

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
por: Azad, Farhan, et al.
Publicado: (2023)

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient
por: Jehn, Ulrich, et al.
Publicado: (2022)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)

Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021)

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
por: Tanaka, Kazuki, et al.
Publicado: (2020)

Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced?
por: Sethi, Ashish, et al.
Publicado: (2021)

Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
por: Ellithi, Moataz, et al.
Publicado: (2021)

A Case of Atypical Hemolytic Uremic Syndrome in a Pregnant Patient
por: Ghazanfar, Haider, et al.
Publicado: (2022)

Atypical Hemolytic Uremic Syndrome Secondary to Pancreatitis: A Case Report
por: Kajiyama, Tsubasa, et al.
Publicado: (2023)

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017)

Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab
por: Ehren, Rasmus, et al.
Publicado: (2021)

Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
por: Schmidt, Tilman, et al.
Publicado: (2022)

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
por: Wang, Yan, et al.
Publicado: (2023)

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome and Life-Long Kidney Failure
por: Mirza, Mohsin, et al.
Publicado: (2022)

The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center
por: Thomas, Katharine, et al.
Publicado: (2023)

A Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
por: Thajudeen, B., et al.
Publicado: (2013)

Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab
por: Webb, Tennille N., et al.
Publicado: (2015)

Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab
por: Raufi, Alexander G., et al.
Publicado: (2016)

Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Atypical Hemolytic Uremic Syndrome After Liver Transplant Treated With Eculizumab
por: Bhatti, Sundus, et al.
Publicado: (2020)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

189 Eculizumab Therapy for Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Publicado: (2021)

Atypical Hemolytic Uremic Syndrome Caused by a Rare Complement Factor B Mutation
por: Bandaru, Sai Samyuktha
Publicado: (2022)

Comparative Safety and Efficacy of Immunosuppressive Regimens Post-kidney Transplant: A Systematic Review
por: Qayyum, Shahid, et al.
Publicado: (2023)

A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome
por: Quiroga, Borja, et al.
Publicado: (2016)

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012)

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
por: Vilalta, Ramon, et al.
Publicado: (2012)

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
por: Tsai, Han-Mou, et al.
Publicado: (2014)

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
por: Andries, Gabriela, et al.
Publicado: (2017)

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2019)

COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy
por: Gill, Jasmeet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eltouield1obsd3h9hplfgsptc